Search

Displaying results 2541 - 2550 of 4234 in total
  1. Drug

    GI-5005

    go.drugbank.com/drugs/DB05942
    Investigational

    Tarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as well as an adaptive, antigen specific cellular immune response.

  2. Drug

    Zimelidine

    go.drugbank.com/drugs/DB04832
    ApprovedWithdrawn

    Zimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving

  3. Drug

    Padimate A

    go.drugbank.com/drugs/DB11229
    ApprovedWithdrawn

    In Europe this chemical was withdrawn in 1989 for unstated reasons and in the US it was never approved for use in sunscreens.

  4. Drug

    Protocatechualdehyde

    go.drugbank.com/drugs/DB11268
    Approved

    Also known as protocatechuic aldehyde, protocatechualdehyde is a naturally-occuring phenolic aldehyde that is found in barley, green cavendish bananas, grapevine leaves and root of the herb S. miltiorrhiza

  5. Drug

    Teriflunomide

    go.drugbank.com/drugs/DB08880
    ApprovedInvestigational

    Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis.

  6. Drug

    Meclizine

    go.drugbank.com/drugs/DB00737
    ApprovedInvestigational

    [L6760] Commonly marketed under the brand name Antivert in the U.S., meclizine is available as oral tablets.

    Products: Naus-ease
  7. Drug

    Ethambutol

    go.drugbank.com/drugs/DB00330
    ApprovedInvestigational

    Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis.

  8. Drug

    Naldemedine

    go.drugbank.com/drugs/DB11691
    ApprovedInvestigational

    Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation.

  9. Drug

    Regorafenib

    go.drugbank.com/drugs/DB08896
    ApprovedInvestigational

    Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 201...

  10. Drug

    Rilpivirine

    go.drugbank.com/drugs/DB08864
    ApprovedInvestigational

    [L1030] On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named